

# 1    **Neutrophils Suppress Mucosal-Associated Invariant** 2    **T Cells**

3

4    Schneider M<sup>1</sup>, Hannaway RF<sup>1</sup>, Lamichhane R<sup>1</sup>, de la Harpe SM<sup>2</sup>, Tyndall JDA<sup>2</sup>, Vernall AJ<sup>2</sup>, Kettle A<sup>3</sup>,  
5    Ussher JE<sup>1\*</sup>.

6    <sup>1</sup>Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand

7    <sup>2</sup>School of Pharmacy, University of Otago, Dunedin, New Zealand

8    <sup>3</sup>Department of Pathology, University of Otago, Christchurch, New Zealand

9    \*corresponding author

10

11

## 12    **Abstract**

13    Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes that are abundant in  
 14    mucosal tissues and the liver where they can respond rapidly to a broad range of riboflavin  
 15    producing bacterial and fungal pathogens. Neutrophils, which are recruited early to sites of  
 16    infection, play a non-redundant role in pathogen clearance and are crucial for controlling infection.  
 17    The interaction of these two cell types is poorly studied. Here, we investigated both the effect of  
 18    neutrophils on MAIT cell activation and the effect of activated MAIT cells on neutrophils. We show  
 19    that neutrophils suppress the activation of MAIT cells by a cell-contact and H<sub>2</sub>O<sub>2</sub> dependent  
 20    mechanism. Moreover, highly activated MAIT cells were able to produce high levels of TNFα that  
 21    induced neutrophil death. We therefore provide evidence for a negative regulatory feedback  
 22    mechanism in which neutrophils prevent over-activation of MAIT cells and, in turn, MAIT cells limit  
 23    neutrophil survival.

24

## 25 Introduction

26 Mucosal-associated invariant T (MAIT) cells are innate-like T cells that are rapidly activated by a  
27 broad range of bacterial and fungal pathogens.<sup>1</sup> MAIT cells are characterised by a semi-invariant  
28 T cell receptor (TCR), V $\alpha$ 7.2-J $\alpha$ 12/20/33, and are restricted by the MHC class I-related protein 1,  
29 MR1.<sup>2</sup> Their activating ligand is derived from 5-amino-6-D-ribitylaminouracil (5-A-RU), an  
30 intermediate in the riboflavin synthesis pathway, which is common in bacteria and fungi, but absent  
31 in humans.<sup>3, 4</sup>

32 MAIT cells represent the most abundant innate-like T cell subset in human blood, comprising  
33 approximately 5% of T cells, and are enriched at mucosal sites, including the lungs and liver.<sup>1</sup> MAIT  
34 cells are rapidly activated in response to riboflavin-producing bacteria via a TCR-dependent  
35 mechanism, producing effector cytokines (interferon- $\gamma$  (IFN $\gamma$ ), tumour necrosis factor  $\alpha$  (TNF $\alpha$ ), and  
36 interleukin-17 (IL-17)), showing cytotoxic potential (through release of perforin and granzymes), and  
37 undergoing proliferation.<sup>5, 6, 78</sup> TCR-independent activation by cytokine stimulation, including by IL-12  
38 and IL-18, results in a comparatively delayed response and altered effector responses.<sup>6, 8</sup>

39 MAIT cells have been shown to influence various immune cell subsets to promote activation of the  
40 adaptive immune response. In a mouse model of *Francisella tularensis* pulmonary infection,  
41 monocyte differentiation to monocyte-derived dendritic cells was driven by the MR1-independent  
42 production of GM-CSF by MAIT cells, affecting recruitment and activation of CD4<sup>+</sup> T cells.<sup>9, 10</sup>  
43 MAIT cells can furthermore instruct dendritic cell (DC) maturation *in vitro* through a CD40L and MR1-  
44 dependent mechanism, promoting IL-12 production.<sup>11</sup> Additionally, in a TCR-dependent manner,  
45 MAIT cells can provide help to B cells, inducing plasmablast differentiation and antibody production  
46 *ex vivo*.<sup>12</sup> Overall, alongside their cytotoxic effector functions, MAIT cells appear to have important  
47 immune modulatory functions, particularly for regulation of myeloid cells.

48 Neutrophils are the most numerous myeloid cell type in the blood and play a crucial role in pathogen  
49 clearance.<sup>13, 14, 15</sup> They are rapidly recruited to sites of inflammation.<sup>15</sup> MAIT cells are able to produce

IL-17A, which can promote the production of the neutrophil chemokine CXCL8.<sup>7, 16, 17</sup> In addition, activated MAIT cells can directly induce neutrophil chemotaxis.<sup>8</sup> Therefore, MAIT cells may play a role in the recruitment of neutrophils to the site of infection. However, little is known about the interaction between neutrophils and MAIT cells at the site of infection. Neutrophils have been shown to suppress activation of conventional T cells and innate-like T cells, including  $\gamma\delta$  T cells and invariant natural killer T (iNKT) cells,<sup>18, 19, 20, 21</sup> however, their effect on MAIT cell activation is yet to be explored. Similarly, the effect of activated MAIT cells on neutrophils has been sparsely studied. Davey *et al.* showed that both V $\delta$ 2<sup>+</sup>  $\gamma\delta$  T cells and MAIT cells had a protective effect on neutrophil survival and induced an antigen presenting phenotype in neutrophils, dependent on GM-CSF, IFN $\gamma$ , and TNF $\alpha$ .<sup>22</sup>

Here, we set out to investigate the relationship between neutrophils and MAIT cells in the presence of a bacterial stimulus. We aimed to understand how neutrophils influence MAIT cell activation and, in turn, how ligand activated MAIT cells affect neutrophils to better understand their roles in response to bacterial infection.

64

## 65 Results

### 66 Neutrophils are poor activators of MAIT cells and suppress MAIT cell activation

67 To assess if neutrophils are able to activate MAIT cells in response to bacteria, neutrophils and  
68 Vα7.2<sup>+</sup> cells (referred to as MAIT cells) were incubated with fixed *E. coli* for 6 or 22 hours. MAIT cell  
69 activation was assessed by intracellular cytokine staining for IFNγ and TNFα (Figure 1A). Neutrophils  
70 were unable to stimulate significant IFNγ production by MAIT cells at either 6 or 22 hours, or TNFα  
71 production at 6 hours (Supplementary figure 1A-C). However, a small population of MAIT cells were  
72 stimulated to produce TNFα at 22 hours, which was dependent on MR1 but not IL-12 (Figure 1B). To  
73 investigate whether the presence of another antigen presenting cell may enhance activation, CD14<sup>+</sup>  
74 monocytes were added to the co-culture. MAIT cells were activated well in the presence of CD14<sup>+</sup>  
75 monocytes alone, however this activation was significantly reduced with addition of neutrophils and  
76 did not differ significantly from MAIT cell activation in the presence of neutrophils alone  
77 (Figure 1C+D). Consistent with the effect observed with *E. coli* treatment, neutrophils alone were  
78 poor activators of MAIT cells with 5-A-RU treatment and suppressed MAIT cell activation by  
79 monocytes (Figure 1E+F). Little IFNγ production was seen with 5-A-RU treatment, but a similar  
80 proportion of MAIT cells produced TNFα in response to 5-A-RU as the co-cultures treated with *E. coli*  
81 (Figure 1E+F). Neutrophil mediated suppression of MAIT cell TNFα production was significant, but  
82 not IFNγ production.

83 Analysis of monocyte activation, as assessed by TNFα production in CD14<sup>+</sup> cells, showed no  
84 significant effect of neutrophils on monocyte activation. Treatment with fixed *E. coli* resulted in  
85 TNFα production in over 90% of monocytes after 6 hours of incubation, regardless of neutrophil  
86 presence or absence (Figure 1G). A trend towards suppression of activation was seen with  
87 neutrophil presence when mean fluorescence intensity (MFI) was assessed, however, this did not  
88 reach significance (Supplementary Figure 1D). Therefore, neutrophils suppress the activation of  
89 MAIT cells, but have no significant effect on CD14<sup>+</sup> monocyte activation.

Next, we investigated whether this suppression of MAIT cells by neutrophils is similarly evident in whole PBMCs. As neutrophils have previously been shown to suppress  $\gamma\delta$  T cell activation, comparison was made to the effect of neutrophils on  $V\delta 2^+$   $\gamma\delta$  T cell ( $V\delta 2^+$  T cell) activation.<sup>19</sup> To ensure the effect seen was not as a result of bacterial phagocytosis by neutrophils, PBMCs were treated in one of two ways: cells were mixed with equal numbers of neutrophils and co-cultured (c) directly with fixed *E. coli* for 6 hours, or PBMCs were pre-incubated (p) with fixed *E. coli* for 20 min and then washed before neutrophil addition. MAIT cell and  $V\delta 2^+$  T cell activation were analysed by flow cytometry for activation marker expression (Figure 2A). The presence of neutrophils significantly inhibited the activation of both MAIT cells and  $V\delta 2^+$  T cells in PBMCs independently of neutrophil exposure to bacteria. MAIT cells and  $V\delta 2^+$  T cells showed a marked decrease in TNF $\alpha$  and IFN $\gamma$  production alongside reduced CD69 upregulation and, for MAIT cells but not  $V\delta 2^+$  T cells, 4-1BB upregulation (Figure 2B+C). While degranulation, as measured by CD107a surface expression, was significantly suppressed in MAIT cells in the presence of neutrophils, no significant change was seen in the expression of granzyme B and perforin in either cell subset (Figure 2C). As previously reported,  $V\delta 2^+$  T cells generally expressed higher levels of both granzyme B and perforin than MAIT cells.<sup>23, 24, 25</sup> IL-17A production was insubstantial both in the absence and presence of neutrophils in both cell types (Figure 2C).

The effect of neutrophils on monocyte activation in PBMCs was analysed by TNF $\alpha$  expression in CD14<sup>+</sup> monocytes. Over 90% of monocytes expressed TNF $\alpha$  in response to *E. coli* treatment; this was not significantly affected by the presence of neutrophils (Figure 2D). However, when TNF $\alpha$  expression was assessed by MFI it was significantly reduced with neutrophil presence (Supplementary Figure 1E). Assessment of the effect of neutrophils on markers of activation and antigen presentation, including CD80, CD86, and MR1, on CD14<sup>+</sup> monocytes in response to *E. coli* treatment showed no significant effect. However, HLA-DR expression on CD14<sup>+</sup> monocytes was significantly increased in the presence of neutrophils in untreated, but not *E. coli* treated, samples (Figure 2E).

Overall, this data shows that neutrophils are poor activators of MAIT cells and have an inhibitory effect on the activation of MAIT cells and  $V\delta 2^+$  T cells in the presence of other antigen presenting cells. This observed suppression appears to be a direct effect of neutrophils on MAIT cells and  $V\delta 2^+$  T cells, as neutrophils had little effect on the activation or phenotype of  $CD14^+$  monocytes.

### **Mechanism of suppression**

Following the above findings, we went on to investigate the mechanism through which neutrophils suppress MAIT cells. Firstly, to determine if the inhibition of MAIT cell activation by neutrophils was dependent on neutrophil viability, we analysed the ability of fixed neutrophils to suppress the activation of MAIT cells. Fixed neutrophils were less able to inhibit MAIT cell activation, showing only a mild suppression of IFN $\gamma$  production (Figure 3A). In contrast,  $V\delta 2^+$  T cell activation was suppressed by fixed neutrophils equivalently to fresh neutrophils (Figure 3A). Next, to analyse the importance of cell contact on neutrophil inhibition of MAIT cell and  $V\delta 2^+$  T cell activation, neutrophils and PBMCs were separated using transwell plates. Control plates lacking transwells were analysed in parallel. The inhibitory effect of neutrophils on MAIT cell and  $V\delta 2^+$  T cell activation was abolished with neutrophil and PBMC separation; no reduction of TNF $\alpha$  and IFN $\gamma$  production was seen in samples separated by transwells. The loss of this suppressive effect of neutrophils was not overcome by using three times the amount of neutrophils (Figure 3B).

Neutrophils have been shown to inhibit conventional T cells through a cell contact-dependent mechanism involving MAC-1 (CD18/CD11b) and the release of reactive oxygen species (ROS), including hydrogen peroxide ( $H_2O_2$ ).<sup>20</sup> We tested if this mechanism was responsible for the inhibitory effect seen on MAIT cells and  $V\delta 2^+$  T cells. Blocking of MAC-1 with an antibody against CD11b did not prevent the inhibitory effect of neutrophils on TNF $\alpha$  and IFN $\gamma$  production by MAIT cells and  $V\delta 2^+$  T cells (Figure 3C, Supplementary Figure 2A). In contrast, removal of  $H_2O_2$  through catalase addition reversed the suppressive effect of neutrophils on MAIT cells and  $V\delta 2^+$  T cells. Both TNF $\alpha$  and IFN $\gamma$  production in samples treated with catalase were significantly higher than in control

samples and were comparable to PBMCs alone for both cell types (Figure 3C, Supplementary Figure 2A). Catalase treatment of PBMCs alone also lead to significantly higher TNF $\alpha$  production in V $\delta$ 2<sup>+</sup> T cells (Supplementary Figure 2A).

Neutrophils have further been described to inhibit T cell function through the release of arginase, resulting in the degradation of arginine, which is required for the expression of the CD3  $\zeta$ -chain (CD3 $\zeta$ ) on T cells.<sup>26, 27, 28</sup> Thus, low levels of arginine can affect T cell activation. Supplementation with L-arginine partially reduced the inhibitory effect of neutrophils on MAIT cells and V $\delta$ 2<sup>+</sup> T cells. TNF $\alpha$  expression was significantly higher than in control samples for both cell types (Figure 3D), though this effect was not consistently evident when production of IFN $\gamma$  was assessed (Supplementary Figure 2D). TNF $\alpha$  production by V $\delta$ 2<sup>+</sup> T cells in PBMCs alone was slightly increased with L-arginine treatment (Figure 3D). Inhibition of arginase with either nor-NOHA or L-valine did not reverse the suppressive effect of neutrophils on MAIT and V $\delta$ 2<sup>+</sup> T cell activation (Figure 3D, Supplementary Figure 2B-D).

Both supplementation of L-arginine and addition of catalase prevented the inhibitory effect of neutrophils on CD107a upregulation on MAIT cells and V $\delta$ 2<sup>+</sup> T cells (Supplementary Figure 3A). The effect of these treatments on granzyme B, perforin, and IL-17A expression was not as clear (Supplementary Figure 3B-D). A slight reduction of granzyme B expression in both cell types was seen in samples where neutrophils were present. This reduction was not seen in samples treated with catalase, however, the difference between non-catalase and catalase treated samples was not statistically significant (Supplementary Figure 3B).

CD3 $\zeta$  expression on MAIT and V $\delta$ 2<sup>+</sup> T cells was significantly reduced when neutrophils were present, even in untreated samples (Figure 3E). In contrast, CD3 $\epsilon$  expression was significantly increased in the presence of neutrophils, and TCR expression was increased in MAIT cells but decreased in V $\delta$ 2<sup>+</sup> T cells (Supplementary Figure 3E-F). L-arginine treatment did slightly increase CD3 $\zeta$  expression, but not to the level of that in PBMCs alone. Addition of catalase did not significantly alter CD3 $\zeta$



expression in either cell type. Interestingly, CD3 $\zeta$  was expressed at higher levels by V $\delta$ 2<sup>+</sup> T cells than MAIT cells, and in response to bacteria MAIT cells slightly downregulated CD3 $\zeta$ , whereas it was slightly upregulated by V $\delta$ 2<sup>+</sup> T cells (Figure 3E).

Another mechanism of T cell suppression is through adenosine. Binding of adenosine to adenosine receptors on T cells can inhibit or skew effector cytokine production. In iNKT cells it has been observed that adenosine inhibits IFN $\gamma$  production but induces IL4 production.<sup>29</sup> Neutrophils are known to be a source of extracellular adenosine,<sup>30, 31, 32</sup> therefore, we tested if this might be a mechanism through which neutrophils inhibit MAIT cell and V $\delta$ 2<sup>+</sup> T cell activation. Treatment of *E. coli* stimulated samples with the adenosine receptor antagonist, ZM241385, did not influence the effect of neutrophils on MAIT cell or V $\delta$ 2<sup>+</sup> T cell activation (Supplementary Figure 4).

Overall, the inhibitory effect of neutrophils on MAIT cell and V $\delta$ 2<sup>+</sup> T cell activation appeared to be dependent on cell contact, ROS but not MAC-1, partially on arginine concentration, and, for MAIT cells, on neutrophil viability.

### **Activated MAIT cells kill neutrophils**

Previously, CD3/CD28 bead activated MAIT cells have been reported to protect against neutrophil death.<sup>22</sup> Here, we tested if ligand activated MAIT cells similarly promote neutrophil survival. V $\alpha$ 7.2<sup>+</sup> (MAIT) cells were isolated and activated for either 4 or 24 hours using the MAIT cell ligand precursor, 5-A-RU, and adherent THP1 cells. 5-A-RU reacts non-enzymatically with methylglyoxal or glyoxal, present in metabolising cells, to form the MAIT cell activating ligand. Activated MAIT cells or conditioned media from the activation cultures were added to freshly isolated autologous neutrophils (Figure 4A). Neutrophil survival was measured by both Annexin V staining after 5 hours, as well as CD16 and viability staining after 24 hours. Adherent THP1 cells treated with 5-A-RU (control) or co-cultured untreated THP1 cells and MAIT cells (UT) were used as controls. Neutrophils treated with supernatant from either 4 or 24 hour activated MAIT cells showed poorer survival compared to control samples. The frequency of both Annexin V positive cells and dead cells were

increased in samples treated with conditioned media from activated MAIT cells (Figure 4B+C). Neutrophils co-cultured with 4 hour pre-activated MAIT cells (at a ratio 1:5 MAIT cells to neutrophils) also showed higher levels of cell death, but not significantly higher Annexin V staining. This effect was dependent on the ratio of neutrophils to MAIT cells, with fewer MAIT cells (ratio 1:10 and 1:50 MAIT cells to neutrophils) resulting in less cell death, and returning to the level in control samples at the 1:50 ratio (Figure 4D+E). A reduction of Annexin V staining was also observed when neutrophils were treated with fewer MAIT cells (Figure 4D). In contrast, neutrophils treated with 24 hour activated MAIT cells showed no change in neutrophil viability and minimal change in Annexin V staining (Figure 4F+G). Treatment of neutrophils with 4 or 24 hour activated MAIT cells significantly reduced the frequency of CD16<sup>high</sup> neutrophils; when fewer MAIT cells were added, the frequency of CD16<sup>high</sup> neutrophils increased (supplementary figure 5A-B). Treatment with conditioned media from activated MAIT cells also lead to reduced frequencies of CD16<sup>high</sup> neutrophils, although the differences were not statistically significant (supplementary figure 5C). Comparison of Annexin V and dead cell staining of neutrophils treated with conditioned media or cells from the controls (loosened adherent THP1 cells treated with 5-A-RU (control) and co-cultures of untreated adherent THP1 cells and MAIT cells (UT)) revealed a small reduction of Annexin V staining in samples treated with non-activated MAIT cells. No other treatment showed any significant effect on neutrophils (Supplementary Figure 5D-E).

### **The amount of TNFα produced by MAIT cells influences neutrophil survival**

Activated MAIT cells rapidly produce high levels of TNFα (see figure 2B).<sup>8</sup> It has been described that high levels of TNFα (>10 ng/mL) induce TNFR dependent apoptosis in neutrophils<sup>33</sup>. Therefore, we analysed whether the killing effect seen by conditioned media from cultures of activated MAIT cells was dependent on TNFα. Addition of a blocking antibody against TNFα significantly inhibited apoptosis and cell death in neutrophils treated with activated MAIT cell conditioned media. Viability staining after 24 hours of incubation was significantly reduced with addition of the TNFα blocking

216 antibody, reducing it to the level of the controls (Figure 5A). Measurement of TNF $\alpha$  in the  
 217 conditioned media of 4 and 24 hour 5-A-RU activated MAIT cells revealed mean concentrations of  
 218 approximately 100 ng/mL and 70 ng/mL, respectively. Therefore, allowing for dilution, neutrophils  
 219 were exposed to mean concentrations of >25 ng/mL and >17 ng/mL, respectively. In control  
 220 samples, mean levels of TNF $\alpha$  between 1-10 ng/mL were measured (exposure of 0.25-2.5 ng/mL,  
 221 respectively) (Figure 5B). Therefore, TNF $\alpha$  production by activated MAIT cells can induce neutrophil  
 222 death.

223

## Discussion

Neutrophils are critical early responders to bacterial infection, phagocytosing and killing microbes.<sup>15</sup> They also regulate the immune response by modulating other immune cells, including T cells.<sup>34</sup> MAIT cells are also important early effector cells during bacterial infection and are present in mucosal tissues. Here, we have investigated the interaction between MAIT cells and neutrophils. We show for the first time that neutrophils suppress the activation of MAIT cells in response to bacteria. The ability of neutrophils to suppress MAIT cell activation was dependent on 1) neutrophil viability, 2) cell contact, 3) H<sub>2</sub>O<sub>2</sub> but not MAC-1, and was independent of 4) arginase, but was weakened by arginine supplementation, and 5) was unaffected by adenosine receptor antagonist, ZM241385. We further investigated the effect of activated MAIT cells on neutrophil survival and found that, in contrast to CD3/CD28 bead activated MAIT cells,<sup>22</sup> 5-A-RU activated MAIT cells produced TNF $\alpha$  at levels able to promote neutrophil death. Therefore, we propose that neutrophils and MAIT cells negatively regulate each other to control inflammation.

The effect of neutrophils on MAIT cell activation was investigated by assessment of a broad range of activation markers; comparison was made to another prominent innate-like T cell population, V $\delta$ 2<sup>+</sup> T cells. IFN $\gamma$  and TNF $\alpha$  production was substantially suppressed in both cell subsets, as was upregulation of CD69. In MAIT cells only, upregulation of 4-1BB and degranulation marker CD107a was also inhibited. Neutrophils did not have any significant effect on granzyme B, perforin, or IL-17A expression. Therefore, we can conclude that neutrophils suppress MAIT cell and V $\delta$ 2<sup>+</sup> T cell activation and do not induce a major change in their effector phenotype. For MAIT cells, this suppression was seen both in co-culture of isolated cells as well as in whole PBMCs. The suppressive effect was maintained both when bacteria were pre-incubated with PBMCs and when MAIT cells were activated with 5-A-RU alone; this eliminated phagocytosis of bacteria by neutrophils as the cause of the suppression. In both co-culture and whole PBMC experiments, the presence of neutrophils had minimal effect on monocyte activation. Therefore, it is probable that neutrophils act

directly on MAIT and V $\delta$ 2<sup>+</sup> T cells. This is supported by the observation that neutrophils interact directly with  $\gamma\delta$  T cells.<sup>19</sup> Moreover, neutrophils have been shown to inhibit conventional T cell activation through a cell contact-dependent mechanism involving MAC-1 (CD11b/CD18) and the localised release of H<sub>2</sub>O<sub>2</sub> in an immunological synapse.<sup>20</sup> Suppression of MAIT cells and V $\delta$ 2<sup>+</sup> T cells by neutrophils was dependent on H<sub>2</sub>O<sub>2</sub>, but not MAC-1, and cell contact was required. Neutrophils have similarly been implicated in the suppression of invariant natural killer cells (iNKT) through an unidentified cell contact-dependent mechanism.<sup>18</sup> It is plausible that suppression of these two innate-like lymphocyte subsets is dependent on the interaction of other surface molecules which have either a direct inhibitory effect, such as PD-1,<sup>35</sup> or facilitate cell binding, in addition to soluble factors, such as H<sub>2</sub>O<sub>2</sub>. Therefore, it is likely that neutrophils are able to affect activation of innate-like lymphocytes through a generalised mechanism dependent on cell contact, or proximity, and soluble factors.

Neutrophil viability was important for MAIT cell inhibition, however, the inhibition of V $\delta$ 2<sup>+</sup> T cell activation was not dependent on neutrophil viability. Sabbione *et al.* previously showed that  $\gamma\delta$  T cell inhibition was dependent on viability.<sup>19</sup> This contradiction may be explained by different experimental setups. Sabbione *et al.* used isolated  $\gamma\delta$  T cells and activated these using the V $\delta$ 2<sup>+</sup> T cell ligand, (E)-4-Hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), whereas we used whole PBMCs and a bacterial stimulus for activation.

The release of arginase by neutrophils and the resulting reduction in arginine concentration has previously been described to inhibit T cell activation through the downregulation of the CD3 $\zeta$ -chain.<sup>36, 37, 38</sup> Indeed, CD3 $\zeta$  expression in both MAIT and V $\delta$ 2<sup>+</sup> T cells was drastically reduced in the presence of neutrophils. L-arginine supplementation slightly increased CD3 $\zeta$  expression in MAIT cells and V $\delta$ 2<sup>+</sup> T cells, however, CD3 $\zeta$  expression was still significantly lower than in PBMC samples alone. Therefore, the effect of neutrophils on CD3 $\zeta$  expression cannot be explained by changes in L-arginine concentration alone. The potential of neutrophils to suppress MAIT cells and V $\delta$ 2<sup>+</sup> T cells

was reduced when L-arginine was added, however, inhibition of arginase using either L-valine or nor-NOHA did not have an effect. A previous report found arginine supplementation had no effect on neutrophil suppression of  $\gamma\delta$  T cells, though this was assessed using only one activation marker, CD25, and the experimental setup differed to this study.<sup>19</sup> In addition to arginase activity, neutrophils are able to rapidly deplete exogenous arginine through importation and nitric oxide synthase (NOS) mediated metabolism to nitric oxide (NO) and citrulline.<sup>39</sup> Future experiments should examine the effect of blocking NOS activity alone, as well as in combination with arginase inhibition, as these enzymes are known to compete for arginine.<sup>40</sup>

Previously, CD3/CD28 bead activated MAIT cells were shown to promote neutrophil survival, which was dependent on TNF $\alpha$ , IFN $\gamma$ , and GM-CSF.<sup>22</sup> The levels of TNF $\alpha$  produced in response to CD3/CD28 bead activation were, on average, over 1 ng/mL and less than 10 ng/mL. In our experimental setup, levels of TNF $\alpha$  were significantly higher, with 5-A-RU activated MAIT cells producing an average of over 100 ng/mL TNF $\alpha$ . High concentrations (>10 ng/mL) of TNF $\alpha$  have been shown to induce TNFR dependent apoptosis in neutrophils.<sup>33</sup> Therefore, bead activation of MAIT cells results in a much milder activation of MAIT cells; not enough to produce sufficient TNF $\alpha$  to induce neutrophil death. TNF $\alpha$  levels in sputum of patients with acute respiratory distress syndrome and synovial fluid of patients with severe rheumatoid arthritis, have been shown to reach 10 ng/mL, though generally levels are lower than that.<sup>41, 42</sup> We recently found median levels of TNF $\alpha$  of 343 pg/mL (range 4 pg/mL – >7.0 ng/mL) in sputum samples of patients with pneumonia.<sup>43</sup>

We propose a model whereby activated MAIT cells recruit neutrophils to the site of infection<sup>8</sup> and neutrophils suppress MAIT cells, preventing excess activation. At the same time, while moderately activated MAIT cells may support neutrophils survival, strongly activated MAIT cells will induce neutrophil apoptosis in a TNF $\alpha$ -dependent manner. Therefore, the balance between MAIT cells and neutrophils may be an important factor in providing an effective, but controlled immune response.

## Methods

### Cells

Peripheral blood mononuclear cells (PBMCs) were isolated from heparinised blood of healthy donors (collected with informed consent with approval from the University of Otago Human Ethics Committee (Health)) using Lymphoprep (Alere Technologies GmbH, Germany) and centrifugation at 800xg for 30min. PBMCs were used immediately or cryopreserved in foetal bovine serum (FBS) supplemented with 10% dimethyl sulfoxide (DMSO, Sigma Aldrich, USA) and stored in liquid nitrogen. Thawed PBMCs were rested overnight in R10 media (RPMI 1640 containing L-glutamine and supplemented with 1% Penicillin/Streptomycin and 10% FBS (all ThermoFisher Scientific, USA) at 37°C with 5% CO<sub>2</sub>. Neutrophils were isolated as previously using Lymphoprep separation.<sup>44</sup> Vα7.2<sup>+</sup> cells (referred to as MAIT cells) and CD14<sup>+</sup> cells (referred to as CD14<sup>+</sup> monocytes) were isolated using an anti-Vα7.2-PE labelled antibody (3C10; BioLegend, USA) and anti-PE microbeads or CD14 microbeads (Miltenyi Biotec, Germany), respectively, as per the manufacturer's instructions. THP1 cells were cultured in R10 media. All experiments were performed in flat-bottom 96-well plates (ThermoFisher Scientific, USA), unless otherwise stated.

### Antibodies and Dyes

The following antibodies and labelled proteins were used: Vα7.2 PE (3C10), Vα7.2 PE-Cy7 (3C10), CD3 BV510 (OKT3), CD3 PE-Cy7 (UCHT1), CD14 BV605 (M5E2), CD15 Pacific Blue (W6D3), CD15 PE-Cy7 (W6D3), CD16 BV510 (3G8), CD69 FITC (FN50), CD80 FITC (2D10), CD86 APC (IT2.2), CD107a PE (H4A3), CD137 (4-1BB) BV421 (4B4-1), CD247 (CD3ζ) FITC (6B10.2), granzyme B FITC (QA16A02), HLA-DR AF700 (LN3), IFNγ PerCP-Cy5.5 (4S.B3), IL-17A PE/Dazzle 594 (BL168), MR1 PE (26.5), Perforin PerCP-Cy5.5 (B-D48), TNFα FITC (MAb11), Vδ2 Pacific Blue (B6), Vδ2 PerCP (B6), Annexin V AF647 (Annexin A5) (all BioLegend, USA), CD161 APC (191B8, Miltenyi Biotec, Germany). Samples were stained with Live/Dead fixable near IR dye (ThermoFisher Scientific, USA).

## **Inhibitors, Cytokines and Functional Antibodies**

The following antibodies were used for blocking experiments: anti-IL-12 (Miltenyi Biotec, Germany), anti-MR1 (26.5), anti-CD11b (ICRF44), anti-TNF $\alpha$  (MAb11), and IgG1 (MOPC-21) and IgG2a (MOPC-173) isotype controls (all BioLegend, USA). Catalase from *Corynebacterium glutamicum*, L-arginine, L-valine, and ZM241385 were purchased from Sigma-Aldrich (USA), and nor-N<sup>ω</sup>-hydroxy-L-arginine (nor-NOHA) from Cayman Chemical (USA).

## **Bacteria**

*E. coli* (HB101) were grown overnight in Luria Broth (ThermoFisher Scientific, USA). For fixation, *E. coli* were washed twice in phosphate buffered saline (PBS), fixed for 20 min at room temperature in 2% paraformaldehyde/PBS (PFA), and washed twice in PBS. Bacterial concentration was estimated by flow cytometry using 123count eBeads (ThermoFisher Scientific, USA). Ten bacteria per antigen presenting cell/PBMC (bpc) were used, unless otherwise stated.

## **5-A-RU**

5-A-RU was synthesised as described previously.<sup>8</sup>

## **MAIT cell activation**

10<sup>5</sup> V $\alpha$ 7.2<sup>+</sup> cells and 5x10<sup>5</sup> neutrophils (1:5 ratio) were co-cultured for 6 or 24 hours in a flat-bottom 96-well plate and treated with *E. coli* with or without blocking antibodies against MR1, IL-12, or isotype controls. Alternatively, 10<sup>5</sup> V $\alpha$ 7.2<sup>+</sup> cells were co-cultured for 6 or 24 hours with or without 10<sup>5</sup> CD14<sup>+</sup> cells and/or 5x10<sup>5</sup> neutrophils (1:1:5 ratio) and treated with *E. coli* or 2  $\mu$ M 5-A-RU. In some cases, neutrophils were pre-treated with *E. coli* for 30 min, washed, then added to the co-cultures. For experiments with PBMCs, 10<sup>6</sup> cells were mixed with 10<sup>6</sup> neutrophils (1:1 ratio) and treated with *E. coli*. In some cases, PBMCs were pre-treated with *E. coli* for 20 min, washed twice, then mixed with neutrophils. For analysis of MR1 expression, the antibody was mixed with 20% mouse serum (Sigma-Aldrich, USA) in PBS and added at the start of treatment.<sup>45</sup> For analysis of



CD107a, the antibody was added at the start of treatment. Brefeldin A (3 µg/mL, BioLegend, USA) was added for the final 4 hours of culture for the analysis of cytokine expression.

### **Analysis of mechanism of MAIT cell suppression**

Neutrophils were fixed for 10 min in 2% PFA, washed twice in PBS, and resuspended in R10. Co-cultures were treated with 4000 U/mL catalase, 10 µg/mL blocking antibody against CD11b or an isotype control, 5 mM L-arginine, 20 mM L-valine, 500 µM nor-NOHA, or 1 µM ZM241385 (A2AR antagonist) where indicated. For analysis of cytokine expression, brefeldin A (3 µg/mL, BioLegend, USA) was added for the final 4h of culture. Transwell (0.4 µm pore size, polycarbonate membrane; Corning, USA) experiments were performed by addition of  $3.5 \times 10^6$  PBMCs to the bottom well and  $3.5$ - $10.5 \times 10^6$  neutrophils to the top well; appropriate controls were performed alongside in 24-well plates.

### **Effect of activated MAIT cells on neutrophils**

$10^5$  THP1 cells were treated with 20 ng/mL phorbol myristate acetate (PMA, Sigma Aldrich, USA) for 24 hours, washed, and rested for 24 hours, to generate adherent monocyte-derived macrophages.  $2 \times 10^5$  MAIT (Vα7.2<sup>+</sup>) cells were then activated on these adherent THP1 cells for 4 or 24 hours with 2 µM 5-A-RU. Controls containing untreated MAIT cells on THP1 cells or 2 µM 5-A-RU treated THP1 cells without MAIT cells were prepared in parallel. Following, neutrophils were isolated from fresh blood of the same donor.  $0.5$ - $5 \times 10^4$  of 2 µM 5-A-RU-activated Vα7.2<sup>+</sup> (MAIT) cells,  $5 \times 10^4$  untreated MAIT cells, 2 µM 5-A-RU treated THP1 cells (cells that dislodged during pipetting), or 50 µL of their supernatant were mixed with  $2.5 \times 10^5$  neutrophils (200 µL total) and incubated for 5 or 24 hours. In some experiments, 10 µg/mL blocking antibody against TNFα or an isotype control were added.

### **Immunostaining**

Samples were stained with various panels of antibodies against CD3, CD14, CD15, CD16, CD69, CD80, CD86, HLA-DR, CD137 (4-1BB), CD161, and Vδ2, as well as a Live/Dead fixable near IR dye for 25 min at 4°C, washed and fixed for 10 min in 2% PFA at room temperature. For intracellular protein

analysis, samples were washed in PBS and 1X Permeabilization Wash Buffer (BioLegend, USA), prior to staining for CD3, CD247 (CD3 $\zeta$ ), V $\alpha$ 7.2, granzyme B, IFN $\gamma$ , IL-17a, perforin, and TNF $\alpha$  for 25 min at room temperature.

For Annexin V staining, cells were stained with antibodies against CD3, CD15, and CD16 and with Live/Dead fixable near IR dye for 25 min on ice, washed once in PBS and once in annexin binding buffer (10 mM HEPES (pH 7.4), 140 mM sodium chloride, 2.5 mM calcium chloride; all Sigma-Aldrich, USA) prior to staining with Annexin V for 10 min on ice. Samples were kept on ice and acquired immediately on the flow cytometer.

### **Flow Cytometry**

Flow cytometry was performed on a BD FACSCanto II or a BD Fortessa (BD Bioscience, USA). Gating strategies for different panels and experiments are shown in Supplementary Figures 6-7. Analysis was performed with FlowJo version 10.4 (TreeStar, USA).

### **TNF $\alpha$ ELISA**

Conditioned media was analysed for TNF $\alpha$  concentration using the human uncoated ELISA kit with plates from ThermoFisher Scientific (USA). Manufacturer's instructions were followed and plates analysed using the Varioskan Lux plate reader (ThermoFisher Scientific, USA). A second order polynomial (quadratic) fitted standard curve was used to interpolate sample concentrations using GraphPad prism software, version 7.00 (USA).

### **Statistical Analysis**

Data were analysed in GraphPad Prism software version 7.00. Unless otherwise stated, means with the standard error of the mean (SEM) and all data points are shown. Specific statistical tests used are described in the figure legends. Generally, two-tailed, repeated measures one or two-way ANOVA were used with multiple comparisons tests where appropriate. A p value below 0.05 was considered statistically significant.

## Acknowledgements

This work was supported by the Health Research Council (HRC) of New Zealand.

## Author contributions

M.S., R.F.H., R.L. performed the experiments. M.S. analysed the data. M.S., A.K., J.E.U. designed the experiments. M.S., J.E.U. managed the study. S.d.l.H., J.T., A.V., synthesised the 5-A-RU. M.S., J.E.U. conceived the work and wrote the manuscript which was revised and approved by all authors.

## Competing interests

All authors declare no competing interests.

## Corresponding author

Please direct all correspondence to James E. Ussher.

## References

1. Ussher JE, Klenerman P, Willberg CB. Mucosal-associated invariant T-cells: new players in anti-bacterial immunity. *Front Immunol* **5**, 450 (2014).
2. Treiner E, *et al.* Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. *Nature* **422**, 164-169 (2003).
3. Corbett AJ, *et al.* T-cell activation by transitory neo-antigens derived from distinct microbial pathways. *Nature* **509**, 361-365 (2014).
4. Kjer-Nielsen L, *et al.* MR1 presents microbial vitamin B metabolites to MAIT cells. *Nature* **491**, 717-723 (2012).
5. Kurioka A, *et al.* MAIT cells are licensed through granzyme exchange to kill bacterially sensitized targets. *Mucosal Immunol* **8**, 429-440 (2015).
6. Ussher JE, *et al.* CD161<sup>++</sup> CD8<sup>+</sup> T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. *Eur J Immunol* **44**, 195-203 (2014).
7. Dusseaux M, *et al.* Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161<sup>hi</sup> IL-17-secreting T cells. *Blood* **117**, 1250-1259 (2011).
8. Lamichhane R, *et al.* Transcriptional analysis defines TCR and cytokine-stimulated MAIT cells as rapid polyfunctional effector T cells that can coordinate the immune response. *bioRxiv*, 600189 (2019).
9. Meierovics A, Yankelevich WJ, Cowley SC. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. *Proc Natl Acad Sci U S A* **110**, E3119-3128 (2013).
10. Meierovics AI, Cowley SC. MAIT cells promote inflammatory monocyte differentiation into dendritic cells during pulmonary intracellular infection. *J Exp Med* **213**, 2793-2809 (2016).
11. Salio M, *et al.* Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells. *J Immunol* **199**, 2631-2638 (2017).
12. Bennett MS, Trivedi S, Iyer AS, Hale JS, Leung DT. Human mucosal-associated invariant T (MAIT) cells possess capacity for B cell help. *J Leukoc Biol* **102**, 1261-1269 (2017).
13. Vento S, Cainelli F. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. *The Lancet Oncology* **4**, 595-604 (2003).
14. Mestas J, Hughes CCW. Of Mice and Not Men: Differences between Mouse and Human Immunology. *The Journal of Immunology* **172**, 2731-2738 (2004).
15. Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? *Frontiers in physiology* **9**, 113-113 (2018).

- 455 16. Billerbeck E, *et al.* Analysis of CD161 expression on human CD8+ T cells defines a distinct  
456 functional subset with tissue-homing properties. *Proc Natl Acad Sci U S A* **107**, 3006-3011  
457 (2010).  
458
- 459 17. Laan M, *et al.* Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the  
460 airways. *J Immunol* **162**, 2347-2352 (1999).  
461
- 462 18. Wingender G, *et al.* Neutrophilic granulocytes modulate invariant NKT cell function in mice  
463 and humans. *J Immunol* **188**, 3000-3008 (2012).  
464
- 465 19. Sabbione F, *et al.* Neutrophils suppress gammadelta T-cell function. *Eur J Immunol* **44**, 819-  
466 830 (2014).  
467
- 468 20. Pillay J, *et al.* A subset of neutrophils in human systemic inflammation inhibits T cell  
469 responses through Mac-1. *J Clin Invest* **122**, 327-336 (2012).  
470
- 471 21. Kalyan S, Chandrasekaran V, Quabius ES, Lindhorst TK, Kabelitz D. Neutrophil uptake of  
472 nitrogen-bisphosphonates leads to the suppression of human peripheral blood  $\gamma\delta$  T cells.  
473 *Cellular and Molecular Life Sciences* **71**, 2335-2346 (2014).  
474
- 475 22. Davey MS, *et al.* Microbe-specific unconventional T cells induce human neutrophil  
476 differentiation into antigen cross-presenting cells. *J Immunol* **193**, 3704-3716 (2014).  
477
- 478 23. Provine NM, *et al.* Unique and Common Features of Innate-Like Human V $\delta$ 2+  $\gamma\delta$ T Cells and  
479 Mucosal-Associated Invariant T Cells. *Frontiers in Immunology* **9**, (2018).  
480
- 481 24. Bade B, *et al.* Differential expression of the granzymes A, K and M and perforin in human  
482 peripheral blood lymphocytes. *International Immunology* **17**, 1419-1428 (2005).  
483
- 484 25. Kurioka A, *et al.* MAIT cells are licensed through granzyme exchange to kill bacterially  
485 sensitized targets. *Mucosal Immunology* **8**, 429 (2014).  
486
- 487 26. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell  
488 receptor CD3zeta chain expression by L-arginine. *J Biol Chem* **277**, 21123-21129 (2002).  
489
- 490 27. Rotondo R, *et al.* Exocytosis of azurophil and arginase 1-containing granules by activated  
491 polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. *J Leukoc*  
492 *Biol* **89**, 721-727 (2011).  
493
- 494 28. Munder M, *et al.* Suppression of T-cell functions by human granulocyte arginase. *Blood* **108**,  
495 1627-1634 (2006).  
496
- 497 29. Nowak M, *et al.* The A2aR adenosine receptor controls cytokine production in iNKT cells. *Eur*  
498 *J Immunol* **40**, 682-687 (2010).  
499
- 500 30. Barletta Kathryn E, Ley K, Mehrad B. Regulation of Neutrophil Function by Adenosine.  
501 *Arteriosclerosis, Thrombosis, and Vascular Biology* **32**, 856-864 (2012).  
502
- 503 31. Bengtsson T, Zalavary S, Stendahl O, Grenegard M. Release of oxygen metabolites from  
504 chemoattractant-stimulated neutrophils is inhibited by resting platelets: role of extracellular  
505 adenosine and actin polymerization. *Blood* **87**, 4411-4423 (1996).

32. Eltzschig Holger K, *et al.* ATP Release From Activated Neutrophils Occurs via Connexin 43 and Modulates Adenosine-Dependent Endothelial Cell Function. *Circulation Research* **99**, 1100-1108 (2006).
33. Geering B, Gurzeler U, Federzoni E, Kaufmann T, Simon HU. A novel TNFR1-triggered apoptosis pathway mediated by class IA PI3Ks in neutrophils. *Blood* **117**, 5953-5962 (2011).
34. Leliefeld PHC, Koenderman L, Pillay J. How Neutrophils Shape Adaptive Immune Responses. *Frontiers in Immunology* **6**, (2015).
35. Jiang J, *et al.* Mucosal-associated invariant T-cell function is modulated by programmed death-1 signaling in patients with active tuberculosis. *Am J Respir Crit Care Med* **190**, 329-339 (2014).
36. Darcy CJ, *et al.* Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. *Critical care (London, England)* **18**, R163-R163 (2014).
37. Kropf P, *et al.* Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. *European journal of immunology* **37**, 935-945 (2007).
38. Sippel TR, *et al.* Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I. *Clinical Cancer Research* **17**, 6992-7002 (2011).
39. Saini R, Singh S. Inducible nitric oxide synthase: An asset to neutrophils. *Journal of Leukocyte Biology* **105**, 49-61 (2019).
40. Rodriguez PC, Ochoa AC, Al-Khami AA. Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity. *Frontiers in Immunology* **8**, (2017).
41. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. *Chest* **108**, 1303-1314 (1995).
42. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. *Ann Rheum Dis* **49**, 665-667 (1990).
43. Hannaway R, *et al.* Role of Innate-like Lymphocytes in the Pathogenesis of Community Acquired Pneumonia. *bioRxiv*, (2018).
44. Albrett AM, Ashby LV, Dickerhof N, Kettle AJ, Winterbourn CC. Heterogeneity of hypochlorous acid production in individual neutrophil phagosomes revealed by a rhodamine-based probe. *The Journal of biological chemistry* **293**, 15715-15724 (2018).
45. Ussher JE, *et al.* TLR signaling in human antigen-presenting cells regulates MR1-dependent activation of MAIT cells. *Eur J Immunol* **46**, 1600-1614 (2016).

## Figure Legends

### Figure 1: Neutrophils are poor activators of MAIT cells and inhibit MAIT cell activation by monocytes.

**A** Vα7.2<sup>+</sup> cells and neutrophils (1:5 ratio) were activated with 10bpc fixed *E. coli* (**B-D**, and **G**) or 2 μM 5-A-RU (**E-F**) and incubated **B** for 22 hours ± blocking antibodies against MR1 and/or IL-12, or **C-D** for 22 hours or **E-G** 6 hours ± CD14<sup>+</sup> monocytes (1:1 ratio to Vα7.2<sup>+</sup> cells). MAIT cell activation was assessed by intracellular staining for TNFα and IFNγ by flow cytometry. TNFα and/or IFNγ production in MAIT cells (CD161<sup>++</sup>Vα7.2<sup>+</sup>CD3<sup>+</sup>) is shown for **B** (n=7), **C-D** (n=12), **E-F** (n=5), and **G** (n=8). Graphs show mean with SEM. Each data point represents an individual blood donor. **B** Repeated measures one-way ANOVA with Tukey multiple comparisons test, or **C-G** Repeated measures one-way ANOVA with Bonferroni's multiple comparison test of preselected pairs. \* p<0.05, \*\* p<0.01, \*\*\* p<0.001, ns = not significant.

### Figure 2: Neutrophils suppress MAIT and Vδ2<sup>+</sup> T cell activation in PBMCs.

**A** Equal numbers of freshly isolated PBMCs and neutrophils (1x N) were mixed and activated with 10bpc fixed *E. coli* either by adding bacteria to the co-culture (c) (**B**) or by pre-incubating (p) PBMCs with bacteria for 20 min and washing before addition of neutrophils (**B-E**). Control samples without addition of neutrophils (no N) were run in parallel. Samples were incubated for 6 hours, with brefeldin A added for the last 4 hours if cytokine production was assessed. Activation markers were analysed in MAIT cells (CD161<sup>++</sup>Vα7.2<sup>+</sup>CD3<sup>+</sup>) and Vδ2<sup>+</sup> CD3<sup>+</sup> T cells. **B** TNFα, IFNγ, and CD69 expression in MAIT cells (top) and Vδ2<sup>+</sup> T cells (bottom) is shown (n=9 and n=6, respectively). **C** Expression of activation markers 4-1BB (n=9 for MAIT cells; n=6 for Vδ2<sup>+</sup> T cells), CD107a (n=7), granzyme B, perforin, and IL-17A (all n=5) in MAIT cells and Vδ2<sup>+</sup> T cells is presented. **D** TNFα expression (n=8) and **E** geometric mean of fluorescence intensity of CD80, CD86, HLA-DR, and MR1 on CD14<sup>+</sup> monocytes is shown (n=6). **B-E** RM two-way ANOVA with Bonferroni's multiple

comparisons test was performed. Each data point represents an individual blood donor. \*  $p < 0.05$ ,  
\*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ , ns = not significant.

**Figure 3: Neutrophils suppress MAIT cells and  $V\delta 2^+$  T cells by a cell-contact and  $H_2O_2$  dependent mechanism.**

**A** PBMCs were pre-activated with 10bpc fixed *E. coli* for 20 min, washed, and cultured for 6 hours in the absence (no N) or presence of equal numbers (1x N) of freshly isolated, or fixed neutrophils (n=9 for MAIT cells and n=7 for  $V\delta 2^+$  T cells). **B** Pre-activated PBMCs were seeded in the lower compartment of a 0.4  $\mu m$  pore size membrane transwell system and cultured for 6 hours in the absence (no N), presence of equal numbers (1x N), or triple the number (3x N) of freshly isolated neutrophils in the upper compartment. Control plates without transwells were run in parallel.  $TNF\alpha$  and  $IFN\gamma$  expression was assessed by flow cytometry in MAIT (n=6) and  $V\delta 2^+$  T cells (n=7). **C-D** Pre-activated PBMCs were cultured for 6 hours in the absence (no N) or presence of equal numbers (1x N) of freshly isolated neutrophils and treated with **C** an isotype control (10  $\mu g/mL$ ), anti-CD11b blocking antibody (10  $\mu g/mL$ ), or catalase (4000 U/mL) (n=7), or **D** with L-arginine (5 mM) or nor-NOHA (500  $\mu M$ ) (n=6).  $TNF\alpha$  expression by MAIT cells and  $V\delta 2^+$  T cells was assessed by flow cytometry. **E** Untreated (UT) or pre-activated PBMCs (*E. coli* (p)) were cultured for 6 hours in the absence (no N) or presence of equal numbers (1x N) of freshly isolated neutrophils and treated with L-arginine (5 mM) or catalase (4000 U/mL) (n=8). Expression of CD3 $\zeta$  by MAIT and  $V\delta 2^+$  T cells was assessed by flow cytometry. All graphs show mean with SEM. Each data point represents an individual blood donor. **A-E** Repeated measures two-way ANOVA with Bonferroni's multiple comparisons test was performed. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ , ns = not significant.

**Figure 4: Activated MAIT cells kill neutrophils.**

**A** Isolated  $V\alpha 7.2^+$  cells were seeded on adherent PMA-treated THP1 cells at a 2:1 ratio. Cells were either left untreated for 20 hours, then treated with 2  $\mu M$  5-A-RU for 4 hours, or treated with 2  $\mu M$



5-A-RU for 24 hours. Untreated co-cultures (UT) and THP1 cells treated with 2  $\mu$ M 5-A-RU for 24 hours in the absence of V $\alpha$ 7.2<sup>+</sup> cells (Control) were used as controls. Both non-adherent cells and conditioned media were harvested and co-cultured with freshly isolated autologous neutrophils. Annexin V staining (at 5 hours), dead cell staining, and CD16 expression (both at 24 hours) were assessed by flow cytometry. Neutrophils treated with conditioned media were stained for **B** Annexin V (at 5 hours) (n=7) and **C** dead cells (at 24 hours) (n=6). **D** Annexin V staining after 5 hours (n=5) and **E** dead cell staining after 24 hours of neutrophil co-culture with 4 hour 5-A-RU activated MAIT cells at different ratios, as indicated (n=4). **F** Annexin V staining after 5 hours (n=7) and **G** dead cell staining after 24 hours of neutrophil co-culture with 24 hour 5-A-RU activated MAIT cells at different ratios as indicated (n=5). **B-G** All graphs show mean with SEM. Each data point represents an individual blood donor. Repeated measures one-way ANOVA with Tukey's multiple comparisons test was performed. \* p<0.05.

# **Figure 5: MAIT cell killing of neutrophils is TNF $\alpha$ dependent.**

**A** Dead cell staining of neutrophils treated with conditioned media from activated MAIT cells or controls (see Figure 4A) and isotype control or TNF $\alpha$  blocking antibody (both 10  $\mu$ g/mL) for 24 hours, as indicated (n=6). **B** TNF $\alpha$  concentration of conditioned media from activated MAIT cells or controls (see Figure 4A) was assessed by ELISA, as indicated (n=3 for control; n=6 for all others). One THP1 cells only control was tested per experiment, each containing two MAIT cell donors. **C** CD16 and dead cell staining of untreated or 2  $\mu$ M 5-A-RU treated neutrophils cultured with V $\alpha$ 7.2<sup>+</sup> cells alone, or both with or without monocytes for 24 hours (n=9). **A-C** All graphs show mean with SEM. Each data point represents an individual blood donor. RM two-way ANOVA with Bonferroni's multiple comparisons test was performed. \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* p<0.0001.

# **Supplementary Figure 1: Neutrophils are poor activators of MAIT cells.**

V $\alpha$ 7.2<sup>+</sup> cells and neutrophils (1:5 ratio) were activated with 10bpc fixed *E. coli* and incubated **A**  $\pm$  blocking antibodies against MR1 and/or IL-12 for 22 hours, or **B-D**  $\pm$  CD14<sup>+</sup> monocytes (1:1 ratio to

Vα7.2<sup>+</sup> cells) for 6 hours, with brefeldin A added for the final 4 hours. **E** PBMCs were pre-incubated (p) with 10bpc fixed *E. coli* for 20 min prior to washing, addition to neutrophils, and incubation for 6 hours, with brefeldin A added for the final 4 hours. **A** IFNγ (n=7) and **B-C** IFNγ and TNFα (n=2) production in MAIT cells (CD161<sup>+</sup>Vα7.2<sup>+</sup>CD3<sup>+</sup>) is shown. **D-E** geometric mean of fluorescence intensity of TNFα in CD14<sup>+</sup> monocytes is shown for (n=8). Mean with SEM of IFNγ and/or TNFα production in MAIT cells (CD161<sup>+</sup>Vα7.2<sup>+</sup>CD3<sup>+</sup>) or CD14<sup>+</sup> monocytes is shown. Each data point represents an individual blood donor. **A** Repeated measures one-way ANOVA with Tukey multiple comparisons test **B-D** Repeated measures one-way ANOVA with Bonferroni's multiple comparison test of pre-selected pairs was performed. **E** Repeated measures two-way ANOVA with Bonferroni's multiple comparisons test. \*\* p<0.01, \*\*\* p<0.001, ns = not significant.

#### **Supplementary Figure 2: Mechanism of MAIT cell suppression by neutrophils.**

Pre-activated PBMCs were cultured for 6 hours in the absence (no N) or presence of equal numbers (1x N) of freshly isolated neutrophils and treated with **A** an isotype control (10 μg/mL), anti-CD11b blocking antibody (10 μg/mL), or catalase (4000 U/mL) (n=7), or **B** L-arginine (5 mM) or nor-NOHA (500 μM) (n=6), or **C-D** L-arginine (5 mM) or L-valine (20 mM) (n=7). IFNγ (**A**, **B**, and **D**) and TNFα (**C**) expression was assessed by flow cytometry in MAIT cells and Vδ2<sup>+</sup> T cells. **A-D** All graphs show mean with SEM. Each data point represents an individual blood donor. Repeated measures two-way ANOVA with Bonferroni's multiple comparisons test was performed. \* p<0.05, \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* p<0.0001.

#### **Supplementary Figure 3: Suppression of MAIT cells by neutrophils. A-F** Pre-activated PBMCs were

cultured for 6 hours in the absence (no N) or presence of equal numbers (1x N) of freshly isolated neutrophils and treated with L-arginine (5 mM) or catalase (4000 U/mL). Expression of **A** CD107a (n=7), **B** granzyme B (n=5), **C** perforin (n=5), **D** IL-17A (n=5), **E** CD3ε (n=6), and **F** Vα7.2 and Vδ2 (respectively) (n=8) was assessed by flow cytometry on MAIT cells and Vδ2<sup>+</sup> T cells. **A-F** All graphs show mean with SEM. Each data point represents an individual blood donor. Repeated measures

two-way ANOVA with Bonferroni's multiple comparisons test was performed. \*  $p < 0.05$ , \*\*  $p < 0.01$ ,  
\*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ , ns = not significant.

**Supplementary Figure 4: Effect of adenosine on MAIT cell activation.**

**A-B** Pre-activated PBMCs were cultured for 6 hours in the absence (no N) or presence of equal  
numbers (1x N) of freshly isolated neutrophils and treated with ZM241385 (1  $\mu$ M) (n=6). TNF $\alpha$  (**A**)  
and IFN $\gamma$  (**B**) expression was assessed by flow cytometry in MAIT cells and V $\delta$ 2<sup>+</sup> T cells. All graphs  
show mean with SEM. Each data point represents an individual blood donor. Repeated measures  
two-way ANOVA with Bonferroni's multiple comparisons test was performed.

**Supplementary Figure 5: Effect of activated MAIT cells on neutrophil viability. A-C** CD16 staining of  
neutrophils after treatment for 24 hours with **A** 4 hour (n=6), or **B** 24 hour (n=8) 5-A-RU activated  
MAIT cells at different ratios, as indicated, or **C** treated with conditioned media as indicated (n=7). **D**  
Annexin V staining after 5 hours (n=7), or **E** dead cell staining after 24 hours (n=5) of untreated  
neutrophils (-), co-cultured with dislodged control THP1 cells or untreated MAIT cells, or conditioned  
media, as indicated. **A-D** All graphs show mean with SEM. Each data point represents an individual  
blood donor. Repeated measures one-way ANOVA with Tukey's multiple comparisons test was  
performed. \*  $p < 0.05$ , \*\*  $p < 0.01$ .


**Supplementary Figure 6: Gating strategy for identification of MAIT cells, V $\delta$ 2<sup>+</sup> cells, and CD14<sup>+</sup>  
monocytes.**

All cells were gated for single cells, prior to separation into monocyte and lymphocyte subsets. Cells  
were further gated for viable cells, identified by live/dead cell staining. CD14<sup>+</sup> monocytes are defined  
as CD14<sup>+</sup>CD15<sup>-</sup> cells on the monocyte subset. MAIT cells are identified as CD14<sup>-</sup>CD15<sup>-</sup>  
CD3<sup>+</sup>CD161<sup>++</sup>V $\alpha$ 7.2<sup>+</sup> cells and V $\delta$ 2<sup>+</sup> cells are identified as CD14<sup>-</sup>CD15<sup>-</sup>CD3<sup>+</sup>V $\delta$ 2<sup>+</sup> cells, each on the  
lymphocyte subset.







**Supplementary Figure 7: Gating strategy for identification of neutrophils.**





680 All cells were gated for single cells, prior to the identification of neutrophils by forward and side  
681 scatter. Neutrophils were further defined as CD15<sup>+</sup> cells. Gating strategies for additional markers,  
682 CD16<sup>high</sup> and Annexin V, are shown. For each cell subset, dead cells were excluded from analysis by  
683 live/dead staining.



**A**

bioRxiv preprint doi: <https://doi.org/10.1101/745414>; this version posted August 28, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

**B****C****D****E****F****G**





MAIT cells

% positive of MAITs

ns

\*\*\*\*

\*\*\*\*

\*\*\*\*

\*

\*\*\*\*

\*\*\*\*

no N

1x N

fixed N

TNF $\alpha$

IFN $\gamma$

**Vδ2<sup>+</sup> T cells**

% positive of Vδ2<sup>+</sup> T cells

Legend: □ no N, ■ 1x N, ■ fixed N

Marker	Condition	Approx. Mean % Positive	Significance (vs no N)
TNFα	no N	34	-
	1x N	22	**
	fixed N	25	ns
IFNγ	no N	51	-
	1x N	37	***
	fixed N	40	ns

**MAIT cells**

Y-axis: % positive of MAITs

Legend:

- no N (black bars)
- 1x N (green bars)
- 3x N (green bars)

Conditions: cell contact, transwell

Stimuli:  $\text{TNF}\alpha$ ,  $\text{IFN}\gamma$

Significance: \*\*\*\* indicates p < 0.0001.

Condition	Stimulus	no N (%)	1x N (%)	3x N (%)
cell contact	$\text{TNF}\alpha$	~62	~34	~26
	$\text{IFN}\gamma$	~72	~40	~34
transwell	$\text{TNF}\alpha$	~61	~58	~54
	$\text{IFN}\gamma$	~68	~68	~66

**Vδ2<sup>+</sup> T cells**

\*\*\*

\*\*\*\*

no N  
1x N  
3x N

% positive of Vδ2<sup>+</sup> T cells

100  
80  
60  
40  
20  
0

TNF $\alpha$  IFN $\gamma$  TNF $\alpha$  IFN $\gamma$

cell contact transwell

Detailed description: This bar graph displays the percentage of Vδ2+ T cells that are positive for TNFα and IFNγ. The y-axis represents the percentage, ranging from 0 to 100. The x-axis is divided into two main sections: 'cell contact' and 'transwell'. Each section contains two groups of bars for TNFα and IFNγ. Within each group, there are three bars representing different treatment conditions: 'no N' (black), '1x N' (dark blue), and '3x N' (light blue). Error bars are shown for each bar, and individual data points are plotted as dots. In the 'cell contact' section, there are significant differences between 'no N' and '1x N' for TNFα (\*\*\*), and between 'no N' and '3x N' for IFNγ (\*\*\*\*). In the 'transwell' section, no significant differences are indicated.

Condition	Treatment	TNFα (%)	IFNγ (%)
cell contact	no N	~36	~49
	1x N	~18	~24
	3x N	~14	~18
transwell	no N	~31	~45
	1x N	~31	~43
	3x N	~30	~42

bioRxiv preprint doi: <https://doi.org/10.1101/075444>; this version posted August 28, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

**Vδ2<sup>+</sup> T cells**

Y-axis: % TNF $\alpha$ <sup>+</sup> of Vδ2<sup>+</sup> T cells

X-axis: *E. coli* (p)

Legend: □ no N, ■ 1x N

Significance: \*\* (no N, - vs +Catalase), \*\*\*\* (1x N, - vs +Catalase)

<i>E. coli</i> (p)	Treatment	no N (%)	1x N (%)
-	-	~25	~13
+Isotype (10 µg/mL)	-	~27	~14
+αCD11b (10 µg/mL)	-	~24	~14
+Catalase (4000 U/mL)	-	~30	~23

MAIT cells

% TNF $\alpha$ <sup>+</sup> of MAITs

□ no N  
■ 1x N

- +L-Arginine (5 mM) +nor-NOHA (500  $\mu$ M)

*E. coli* (p)

\*

<i>E. coli</i> (p)	Treatment	% TNF $\alpha$ <sup>+</sup> of MAITs (approx. mean)
-	no N	60
	1x N	25
+L-Arginine (5 mM)	no N	62
	1x N	43
+nor-NOHA (500 $\mu$ M)	no N	56
	1x N	21

**Vδ2<sup>+</sup> T cells**

\*\*\* \*\*

% TNF $\alpha$ <sup>+</sup> of Vδ2<sup>+</sup> T cells

no N  
1x N

- +L-Arginine (5 mM) +nor-NOHA (500  $\mu$ M)

*E. coli* (p)

<i>E. coli</i> (p)	Treatment	% TNF $\alpha$ <sup>+</sup> of Vδ2 <sup>+</sup> T cells (approx. mean)
-	no N	16
-	1x N	8
+L-Arginine (5 mM)	no N	25
+L-Arginine (5 mM)	1x N	16
+nor-NOHA (500 $\mu$ M)	no N	16
+nor-NOHA (500 $\mu$ M)	1x N	9

**MAIT cells**

Y-axis: geoMFI CD3 $\zeta$  on MAITs

X-axis: *E. coli* (p)

Legend:

- no N (white bars)
- 1x N (green bars)

Treatments: UT, -, +L-Arginine (5 mM), +Catalase (4000 U/mL)

Significance markers: \*\*\* (UT vs -), \* (- vs +L-Arginine)

<i>E. coli</i> (p)	no N (geoMFI CD3 $\zeta$ )	1x N (geoMFI CD3 $\zeta$ )
UT	~2850	~550
-	~2450	~500
+L-Arginine (5 mM)	~2350	~750
+Catalase (4000 U/mL)	~2500	~550

**V $\delta$ 2<sup>+</sup> T cells**

Y-axis: 0, 2000, 4000, 6000, 8000, 10000








Legend:  no N,  1x N

X-axis: UT, -, +L-Arginine (5 mM), +Catalase (4000 U/mL)


Significance: \*\* (UT), \* (-), \* (+L-Arginine), \* (+Catalase), \* (- to +L-Arginine)

Condition	no N (approx. mean)	1x N (approx. mean)
UT	5500	1000
-	6000	1000
+L-Arginine (5 mM)	5800	1500
+Catalase (4000 U/mL)	6000	1000






**C**



# B



**C**

